FocalTherics (NASDAQ:FOCL) Receives Consensus Recommendation of “Hold” from Brokerages

FocalTherics (NASDAQ:FOCL) has been given an average rating of “Hold” by the five research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $9.00.

Several brokerages have recently weighed in on FOCL. Mizuho set a $15.00 price target on shares of FocalTherics and gave the stock an “outperform” rating in a research note on Friday, July 17th. Wall Street Zen raised FocalTherics to a “hold” rating in a report on Saturday, August 1st. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of FocalTherics in a research report on Tuesday, June 2nd. Finally, Piper Sandler reissued a “neutral” rating on shares of FocalTherics in a report on Friday.

FocalTherics Trading Up 0.2%

NASDAQ FOCL traded up $0.01 during trading hours on Friday, hitting $4.64. 1,495 shares of the company’s stock traded hands, compared to its average volume of 62,962. The stock has a fifty day simple moving average of $5.38. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99. The firm has a market capitalization of $173.91 million, a price-to-earnings ratio of -5.73 and a beta of -0.04. FocalTherics has a 52 week low of $1.30 and a 52 week high of $6.40.

Hedge Funds Weigh In On FocalTherics

A number of hedge funds have recently modified their holdings of the company. Rock Springs Capital Management LP increased its stake in FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock worth $5,126,000 after buying an additional 91,500 shares in the last quarter. Flax Pond Capital LLC bought a new position in shares of FocalTherics during the 4th quarter valued at approximately $2,623,000. Leonteq Securities AG bought a new position in FocalTherics during the fourth quarter valued at $313,000. Kovack Advisors Inc. purchased a new position in FocalTherics in the fourth quarter worth about $53,000. Finally, Lido Advisors LLC purchased a new position in shares of FocalTherics in the 1st quarter worth approximately $40,000. 62.74% of the stock is currently owned by institutional investors.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.